Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,359 | 157 | 1,173 |
| Samples | 503 | 84 | 409 |
| Peptides | 407 | 61 | 347 |
Function
UBE3B · Ubiquitin protein ligase E3B
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin-protein ligases. This gene encodes a member of the E3 ubiquitin-conjugating enzyme family which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme and transfers the ubiquitin to the targeted substrates. A HECT (homology to E6-AP C-terminus) domain in the C-terminus of the longer isoform of this protein is the catalytic site of ubiquitin transfer and forms a complex with E2 conjugases. Shorter isoforms of this protein which lack the C-terminal HECT domain are therefore unlikely to bind E2 enzymes. Alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2012].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 394 amino-acid changes on canonical ENST00000342494 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in UBE3B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in UBE3B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Oral Cavity Carcinoma | 4/54 7% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 30/612 5% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Melanoma | 5/210 2% | 47/1899 2% |
| Colorectal Carcinoma | 12/143 8% | 70/3239 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Gastric Carcinoma | 0/74 0% | 39/1809 2% |
| Germ Cell Tumour | 2/25 8% | 2/169 1% |
| Bladder Carcinoma | 1/58 2% | 18/956 2% |
| Other Solid Cancers | 1/94 1% | 24/1515 2% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Neuroendocrine Tumour | 5/154 3% | 6/577 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 22/1390 2% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Hepatocellular Carcinoma | 3/46 7% | 22/2210 1% |
| Head and Neck Carcinoma | 4/85 5% | 12/1574 1% |
| Non-Cancerous | 0/104 0% | 8/830 1% |
| Ovarian Carcinoma | 4/109 4% | 5/998 0% |
| B-Cell Non-Hodgkins Lymphoma | 5/88 6% | 15/2534 1% |
| Breast Carcinoma | 2/144 1% | 19/3264 1% |
| Prostate Carcinoma | 2/13 15% | 11/2105 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 13/2550 1% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Kidney Carcinoma | 0/85 0% | 9/1862 0% |
| Biliary Tract Carcinoma | 1/54 2% | 3/950 0% |
Mutation Distribution
Where UBE3B is mutated · all tissues, split by cell line vs tissue
How many mutations in UBE3B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,359 mutations in UBE3B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|